

## Neuroendocrine Tumors

### Well Differentiated

#### 1st Line

#### 2nd Line

#### Operable

#### Inoperable

**[NET0030](#)**  
 Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors  
 PI: Visser  
 Sponsor: Stanford University  
 1st Priority

**[NET0028](#)**  
 Phase III [177Lu-Edotreotide vs Targeted Molecular Therapy w/ Everolimus in SSTR+ Neuroendocrine Tumors](#)  
 PI: Aparici  
 Sponsor: ITM Solucin GmbH

**[NET0032](#)**  
 Phase III Peptide Receptor Radionuclide Tx w/ LU-Edotreotide vs SoC in SSTR+ Neuroendocrine Tumors  
 PI: Iagaru  
 Sponsor: ITM Solucin GmbH

**[ECOG-ACRIN-A021602](#)**  
 Phase III [Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus](#)  
 PI: Shahgufta  
 Sponsor: ECOG-ACRIN

**[NET0033](#)**  
 Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Carcinoid Syndrome  
 PI: Shaheen  
 Sponsor: Crinetics Pharmaceuticals, Inc.

#### KEY

- Pending
- Open for Enrollment
- Enrollment on Hold
- Optional Path
- Link Trial Posting
- Extension Study
- Immunotherapy